INTRODUCTION
If transmission of hepatitis C virus (HCV) from an infected healthcare worker (HCW) to a patient is detected, notifi ca tion of other patients of that HCW who have undergone exposure-prone proce dures is usual practice. 1 The Advisory Group on Hepatitis recommend that patient notification exercises (PNEs) should be carried out only when HCW to-patient transmission of HCV has been identified, and where a PNE is carried out, only patients who have undergone a high-risk exposure-prone procedure (EPP) should be notified in the fi rst instance. 2 A PNE is not usually under taken when a HCV RNA positive HCW is identified in the absence of evidence of transmission. There is no guidance in the UK on managing patients exposed to instruments that are possibly contami nated with blood-borne viruses (BBVs). 3 
BACKGROUND
In October 2005, the National Public Health Service for Wales (NPHS) was formally notified of a case of RNA posi tive HCV infection in a HCW who was currently practising in a dental sur gery. An incident management team was established to determine and imple ment all necessary action. Mapping of known HCV cases across the local health board (LHB) area did not demonstrate an excess in the locality surrounding the HCW's practice, and the distribution of the specific genotype was similar to that reported for Wales as a whole. A review of files held by the LHB relating to the practice revealed that concerns had been raised in the past, as a result of routine inspections and two written patient com plaints, regarding the infection control procedures in the practice. The defi cien cies in infection control practice over a ten year period included a failure to con sistently wear gloves while performing EPPs, employ a tray system for sterilis ing instruments and appropriately store instruments after sterilisation.
The incident management team sought advice from the UK advisory panel for healthcare workers infected with blood borne viruses (UKAP). The panel noted that as infection control appeared to have been substandard, there was a risk of transmission of BBVs between patients, as well as transmission of HCV from the HCW to patients. Thus, UKAP advised that all the HCW's patients should be contacted and offered testing for HIV, hepatitis B virus (HBV) and HCV.
Records were available on 6,139 patients who had been treated at the prac tice since 1969. Attempts were made to contact 4,900 of these patients as part of the PNE; it was not possible to trace 587 patients and 652 were deceased. Testing for BBVs was eventually completed on Table 1 Genotyping and sequencing of virus obtained from cases of hepatitis C 2,665 patients. We report the results of a case control study undertaken to inves tigate the association between treatment by the HCW and infection with a BBV.
METHOD
An unmatched nested case control study was undertaken to test whether treat ment by the HCW was associated with infection with a BBV. Cases were all individuals with laboratory evidence of current or past infection with a BBV, identified as a result of the PNE. Con trols were randomly selected individuals tested during the PNE without labora tory evidence of current or past infection with a BBV. Controls were obtained by assigning a random number to the 2,046 individuals who had tested negative by 7 July 2006 using the RAND function in Microsoft Excel. Controls were then selected sequentially from this list start ing with the largest random number.
Study power was calculated using DSS Research researcher's toolkit. 4 The power calculation assumed that the mean number of treatments and stand ard deviation in controls was the same as the whole cohort and that variance of the mean number of treatments in cases would be equal. Four controls were selected per case. This gave the study a statistical power of 75% at the 5% sig nificance level to detect a 50% greater mean number of attendances for treat ment in cases compared to controls.
A standard proforma was designed to record detailed information on the treat ment provided by the HCW for the cases and controls. The data was subsequently obtained from each patient record by two authors (SS and BWM).
The proforma captured age, gender and total number of visits (contacts) for each patient. It was also designed to record the date and types of intervention carried out at each visit. Interventions were classified as non-invasive, mini mally invasive or invasive. A patient could have more then one intervention in a single visit.
Interventions were classifi ed as non invasive if limited to advice, instruc tion or formulation of a treatment plan which did not involve a periodontal An opportunity was given to record in free text any procedure which did not fall into one of the above categories, but was not required. Information on lifetime risk factors for BBV infection was obtained during tel ephone interviews with cases and con trols using a structured questionnaire. The information obtained included details of social history (place of birth, ethnicity, periods living outside the UK, periods of incarceration, living in resi dential accommodation, living with a person with a BBV, hepatitis B status of mother at the time of birth, tattoos, and body piercing) and occupational history (work in healthcare, work in residential accommodation, and work outside the UK). Medical history included details of organ transplants or tissue grafts, renal dialysis, hospital or dental treat ment abroad, hepatitis B immunisation, surgical treatment, blood transfusion and the receipt of other blood products. Sexual history involved the recording of number of lifetime partners, gender of sexual partners, condom use and part ners who used intravenous drugs. Drug history including details of injecting, snorting or other drug use, injecting in the presence of others, sharing needles, syringes or 'works', and sharing spoons, water, filters, or 'paraphernalia'.
Questionnaire data were collated using Epi Info 6.04 5 and odds ratios, 95% con fi dence intervals, chi-square tests, Fish er's exact tests, Mann-Whitney U tests Primary screening tests were per formed on initial serum obtained from patients using multichannel analyser enzyme immunoassays (EIA) for HCV (Abbott AxSym), HBV surface anti gen (Abbott AxSym HBSAg), and HIV (Abbott AxSym Combi Kit HIV 1/2). Equivocal HCV EIA screening tests were resolved using recombinant immunoblot assay (RIBA) for HCV antibodies (Chi ron RIBA HCV 3.0). A second sample was obtained from patients with positive or unresolved equivocal HCV antibody tests to establish viraemia and geno type using real-time polymerase chain reaction (rt-PCR) to detect HCV RNA (Roche). To ascertain if samples of the same genotype were linked to the HCW or each other, sequencing studies of a 222-nucleotide fragment of the NS5B sub-genomic region were undertaken to determine phylogeny and homology. Samples that were positive or equivocal for HBV surface antigen were tested for HBV e antigen, e antibody, core IgM and IgG antibody by EIA (Abbott).
RESULTS
In the 2,665 patients tested for infection, past or present, HCV was confi rmed in 11 patients and past HBV infection was demonstrated in 20 patients. The total number of patients with evidence of BBV infection was 30 because one individual had infection with both HBV and HCV. No patients had evidence of current infection with HBV or infection with HIV. The prevalence of HCV infection was 0.41% (95% CI 0.21% -0.74%) and the prevalence of past HBV infection was 0.75% (95% CI 0.46% -1.16%).
Eight of the 11 patients with HCV had current infection demonstrated by HCV RNA viraemia. Four of these were geno type 1, two genotype 3a, one genotype 2, and one untypeable ( Table 1 ). The HCW was infected with a genotype 3a virus.
The response rate for interviews was 83% (25/30) in cases and 56% (67/120) in controls. All the patient records for cases and controls were available for review. There were no signifi cant differ ences in the age or gender of cases and controls. The mean age of cases was 57 years and controls 55 years (p = 0.57), (14/30) and 36% (43/120) of the controls were male (p = 0.27).
The mean number of visits for treat ment was 20.5 in cases and 18.6 in con trols; the difference 1.8 (95% CI Table 2 ) and HBV infection (Table  3 ) compared to controls.
Statistically signifi cant associations were observed between HCV infec tion and intravenous drug use (OR ∞, p = 0.0001), snorting drugs (OR 40, p = 0.003), a sexual partner who was an intravenous drug user (OR 38, p = 0.003) and having more than ten lifetime sex ual partners (OR 5.1, p = 0.046). Odds ratios of above 3, which did not reach statistical significance, were observed for a history of working in healthcare, working in a residential home for people with learning difficulties, and hospital treatment outside the UK (Table 4) .
Statistically signifi cant associations were observed between HBV infec tion and intravenous drug use (OR ∞, p = 0.006), living with an individual known to have HBV (OR ∞, p = 0.006), originating from a country with a high prevalence of HBV (OR ∞, p = 0.006), working in a residential home for people with learning difficulties (OR 12.5, p = 0.0007), and being born outside the UK (OR 9.3, p = 0.005). Odds ratios of above 8, which did not reach statistical signifi cance, were observed for men who have sex with men, snorting drugs, and a sexual partner who was an intravenous drug user (Table 5) .
DISCUSSION
The observed prevalence of HCV infec tion of 0.41% (95% CI 0.21% -0.74%) is similar to the estimated prevalence of HCV in England of 0.5%. 7 No association between the amount or type of dental treatment and infection with HCV was observed. In the eight cases of HCV who agreed to be interviewed, five gave a Table 4 Univariate analysis of risk factors and cases of hepatitis C from patient interview history of intravenous drug use, three of whom reported sharing needles and the other two reported sharing other para phernalia used to prepare drugs before injection. A sixth case had not used intravenous drugs but reported snort ing heroin. A seventh case had received a blood transfusion in 1987 prior to the introduction of testing blood products for the HCV. The eighth case reported no significant risk factors.
Sequencing of virus isolated from the two patients with genotype 3a infec tion demonstrated that the viruses were not related to the HCW. Similarly the sequencing of HCV from patients infected with the same genotype showed that the virus was unrelated. The four patients from whom virus was unobtain able all had good alternative explana tions for their hepatitis C virus infection. The history of intravenous drug use in two patients, one of whom had a part ner with known hepatitis C infection, a history of blood transfusion prior to the introduction of testing of blood products in the third patient, and a partner with hepatitis C infection, are all more likely sources of infection than transmission from the HCW or another patient. HCV can be transmitted via sexual contact, 8 albeit less efficiently than other BBVs. Although the risk of sexual HCV acqui sition is low, sex is such a common behaviour that it is thought to account for around a fifth of acute HCV infec tions in the USA. 8 Alternatively, other routes of intrafamilial transmission 9 or undisclosed common risk factors may explain infection in partners of known cases of HCV infection.
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There was no evidence which demon strated transmission of HCV from the HCW to a patient or from patient-to patient via inadequate decontamination or contamination of surgical instru ments. The evidence available from patients who presented for testing sug gests that this was extremely unlikely to have occurred. To absolutely exclude transmission, all patients would need to be tested. However, the negative fi ndings in the 43% (2,665/6,138) of patients who were alive, traced and tested suggests that the occurrence of transmission was zero or very low.
No patients tested positive for HIV infection and thus patient-to-patient transmission of HIV did not occur in the patients who were tested. All the patients with HBV infection had resolved or past infection. The absence of circulat ing virus means that it is not possible to investigate the possibility of patient to-patient transmission with genetic sequencing. Epidemiology is the only method available for this investigation.
Data with which to compare the observed prevalence of past HBV infec tion of 0.76% (95% CI 0.46% -1.17%) is limited. A 1998 population-based study in the Republic of Ireland found anti-HBc in 0.29% (5/1,714) of specimens tested.
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A 1996 study of residual diagnostic sera in England and Wales found anti-HBc in 2.5% (75/3,039) of specimens tested from outside of London. 12 However, the prevalence in these selected samples in different areas was highly dependent on the proportion of the population born in Africa and Asia. In the LHB served by the practice, only 1.6% of the popula tion was born outside of the European Union and as a result, the predicted prevalence from these data would be much lower than 2.5%. A study of blood donors in the South West of England in 1979 reported a prevalence of antiHBc of 0.7% in new donors and 0.4% in established donors. 13 The prevalence in West Yorkshire firemen in 1988 was reported as 0.6% (1/173) 14 and in Lanca shire police offi cers 2.8% (8/284). 15 The observed prevalence, 0.76%, of anti-HBc in this investigation is at a level that might reasonably be expected.
No association between the amount or type of dental treatment and infec tion with HBV was observed. Among the 18 cases of HBV that were interviewed, two cases gave a history of intravenous drug use, two cases had an ethic origin and were born in countries with a high prevalence of HBV, one case was a man who had sex with men, one case, who did not have a history of intravenous drug use, had a sexual partner who did and was known to have a history of hepati tis B, two cases, without other risk fac tors, had worked in a residential home for people with learning disabilities, and a ninth case had a history of jaun dice six months after receiving a blood transfusion prior to the introduction of testing blood products for the hepatitis B virus. Risk factors were not identifi ed to explain the remaining nine cases, although an elevated but not statistically significant odds ratio of 2.5 for more than ten sexual partners suggests that a proportion of these cases are likely to be due to heterosexual transmission. These findings are similar to other UK studies in which the probable means of acquisi tion was known for just over half of all adult cases of acute HBV infection. 16 There is no evidence which demon strates patient-to-patient transmission of HBV. The available evidence from the data on prevalence and the case control study suggests that the occurrence of patient-to-patient transmission of the HBV arising from deficiency in infection control practice was zero or low.
The initial risk assessment conducted by the NPHS concluded that the risk of patient-to-patient transmission of a BBV infection was probably very small but not zero. The assessment was reliant on there being a low prevalence of BBV infections in the relevant community rather than on the safety of the infec tion control procedures in operation. Testing demonstrated that the assump tion underpinning this risk assessment was correct.
Transmissions of BBVs from HCWs to patients are well documented. The limited occasions when HIV transmis sion has been demonstrated include a dentist to a patient. 17 Prior to routine immunisation, transmission of HBV between dentist and patient occurred more frequently, but was last described in 1986. 18 Transmission of HCV from a dentist to a patient has never been dem onstrated. 19 In the absence of prior evi dence of transmission, the PNE would not have been undertaken if recommended infection control practice, in particular the consistent use of gloves while per forming EPPs, had been implemented by the HCW. Completion of this investiga tion, which detected no transmission from the HCW to patients, reinforced the judgement that PNEs are not normally indicated and provides evidence to sug gest that PNEs may not be necessary for lower risk EPPs even when the HCW has not consistently worn gloves.
Notification of patients identifi ed as having been exposed to a risk of BBV infection from other patients is under taken to provide patients with informa tion about the nature of the risk to which they have been exposed, detect any BBV infection, provide care to the infected person and advice on measures to pre vent onward BBV transmission, and obtain valid data to augment existing estimates of the risk of BBV transmis sion from patient-to-patient. Although individual and population health gain may have arisen from the detection of incidental cases of HCV in this PNE, 3 who estimated that less than one case of BBV transmis sion would occur following a failure of decontamination of dental instruments and thus took no action following three separate incidents of decontamination failure. A PNE following a dentist's admission of the periodic use of unsteri lised equipment did not detect transmis sion of BBV. 20 Although the risks are low they are not zero, as patient-to-patient transmission of HBV has been described on one occasion in a dental practice. 21 The very significant costs of PNEs probably outweigh the limited benefi ts. Patients who are contacted during PNEs report feeling anxious on receiving the letter, but almost all believe patients should always be informed following treatment by an infectious HCW, even when the risks are very small. 22 The con sequences of infection with a BBV for a HCW are grave and any unnecessary addition to this unfortunate personal experience should be avoided. 19, 23, 24 Patient-to-patient transmission of BBVs was not demonstrated in the PNE despite comprehensive virological and epidemiological investigation. In inci dents where transmission has not been identified, the risk of patient-to-patient trol failures varies within the NHS. We suggest that the National Institute for Health and Clinical Excellence should be asked to produce guidance for the NHS which will combine a robust economic evaluation with the views of stakehold ers including patients.
